NASDAQ$ICUI

ICU Medical Inc. · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

ICU Medical's second quarter results were consistent with expectations, showing growth in most product families except Vascular Access and IV Solutions.

ICU Medical reported second quarter revenue of $549.3 million, a decrease compared to $561.0 million in the same period last year. The company's GAAP gross profit increased to $192.3 million from $167.6 million, with a gross margin of 35% compared to 30% last year. GAAP net loss was $(9.9) million, or $(0.41) per diluted share, while adjusted diluted earnings per share was $1.88. Adjusted EBITDA was $98.1 million, compared to $84.7 million in the same quarter of the previous year.

  • Second quarter revenue reached $549.3 million.
  • GAAP gross profit increased to $192.3 million with a gross margin of 35%.
  • GAAP net loss was $(9.9) million, or $(0.41) per diluted share.
  • Adjusted diluted earnings per share was $1.88.

Headline financials

Total Revenue

$549M

Previous: $561M-2.1%
EPS (adj)

$1.88

Previous: $1.37+37.2%
Adjusted EBITDA

$98.1M

Previous: $84.7M+15.8%
GAAP Gross Margin

35.0%

Previous: 30.0%+16.7%
Capital Expenditures

-$32.5M

Previous: -$48M+32.4%
Free Cash Flow

-$42.4M

Previous: -$55.5M+23.6%
Net Income

-$9.93M

Previous: -$7.47M-32.9%
Operating Income

$2.76M

Previous: -$48K+5850.0%
Gross Profit

$192M

Previous: $168M+14.8%
Cash & Equivalents

$196M

Previous: $256M-23.4%
Total Assets

$4.46B

Previous: $4.59B-2.8%
Stock-Based Comp

$9.77M

Previous: $7.76M+25.9%

Revenue & EPS history

ICU Medical · Revenue · Quarterly

$549M

Q2 2023-2.1%vs Q2 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

ICU Medical · $390M total across 2 segments · Q2 2023

  • Consumables
    $237M+64.0%
  • Infusion Systems
    $153M+75.5%

Forward guidance

ICU Medical narrowed the estimates of the range of its full year 2023 guidance of adjusted EBITDA from a range of $375 million to $425 million to a range of $375 million to $405 million and adjusted diluted earnings per share from a range of $5.75 to $7.25 to a range of $6.00 to $6.85.

Tailwinds

  • Adjusted EBITDA is expected to be between $375 million and $405 million.
  • Adjusted diluted earnings per share are projected to be between $6.00 and $6.85.

Headwinds

  • GAAP net loss is estimated to be in the range of $(59) million to $(38) million.
  • GAAP diluted loss per share is estimated to be in the range of $(2.42) to $(1.57).

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.3%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-0.3%

Avg return

30 days after

52%

38 / 73 earnings

Positive

+22.4%

Q2 2024

Best reaction

-33.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-0.8%+10.7%
Q4 2025+4.8%+3.6%-16.3%
Q3 2025+8.2%+7.3%+9.9%
Q1 2025-3.3%-4.9%-6.9%
Q4 2024-2.3%-4.1%-6.4%
Q3 2024-1.9%-5.8%-7.1%
Q2 2024+22.4%+19.7%+31.2%
Q1 2024-0.1%+6.3%+7.6%
Q4 2023+6.5%-0.2%+1.6%
Q3 2023-17.8%-20.2%-15.9%
Q2 2023-15.2%-15.6%-16.8%
Q1 2023+13.3%+8.7%+3.9%
Q4 2022-3.6%-4.2%-7.3%
Q3 2022+6.7%+21.4%+11.8%
Q2 2022-7.4%-4.7%-8.0%
Q1 2022-10.4%-15.0%-14.9%
Q4 2021+5.8%+9.0%+4.3%
Q3 2021+2.1%+2.7%-6.4%
Q2 2021+0.7%+1.2%+6.1%
Q1 2021-5.0%-6.5%-2.1%
Q4 2020-5.5%-6.8%-4.4%
Q3 2020+0.6%+4.8%+5.6%
Q2 2020+8.8%+5.0%+9.8%
Q1 2020-8.8%-13.7%-8.0%
Q4 2019-4.2%-4.8%-8.2%
Q3 2019+6.9%+4.3%+6.8%
Q2 2019-33.3%-31.2%-36.6%
Q1 2019-2.7%-3.3%-2.2%
Q4 2018+2.5%-4.9%-2.8%
Q3 2018-10.6%-14.8%-10.6%
Q2 2018+2.2%+2.4%+3.7%
Q1 2018+1.4%+4.3%+12.4%
Q4 2017+4.6%+7.5%+9.1%
Q3 2017+8.6%+10.1%+11.7%
Q2 2017-2.9%-2.4%+3.4%
Q1 2017-0.2%-0.1%+6.2%
Q4 2016+0.7%-1.0%+1.5%
Q3 2016-0.4%-0.9%+2.5%
Q2 2016+7.5%+6.1%+8.6%
Q1 2016-1.0%
Q4 2015-8.7%
Q3 2015+5.8%
Q2 2015+19.9%
Q1 2015+7.3%
Q4 2014+2.2%
Q3 2014+13.6%
Q2 2014+10.5%
Q1 2014+3.3%
Q4 2013+0.1%
Q3 2013+3.0%
Q2 2013-6.7%
Q1 2013+1.3%
Q4 2012+1.1%
Q3 2012+3.7%
Q2 2012-0.2%
Q1 2012+0.8%
Q4 2011+1.9%
Q3 2011+0.2%
Q2 2011-3.9%
Q1 2011+2.2%
Q4 2010+0.1%
Q3 2010-0.9%
Q2 2010+3.4%
Q1 2010-1.0%
Q4 2007-1.0%
Q4 2009-1.0%
Q3 2009-0.8%
Q3 2008-0.8%
Q2 2009-0.6%
Q2 2008-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q1 2008-3.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro